Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives

被引：38

作者：

Matsuzaki, Shinya ^{[1
]}

Yoshino, Kiyoshi ^{[1
]}

Ueda, Yutaka ^{[1
]}

Matsuzaki, Satoko ^{[1
]}

Kakuda, Mamoru ^{[1
]}

Okazawa, Akiko ^{[1
]}

Egawa-Takata, Tomomi ^{[1
]}

Kobayashi, Eiji ^{[1
]}

Kimura, Tadashi ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan

来源：

CANCER CELL INTERNATIONAL | 2015年 / 15卷

关键词：

Clear cell carcinoma; Platinum resistance; Annexin A4; Target-based therapies; Ovarian cancer; GROWTH-FACTOR RECEPTOR; PROMISING THERAPEUTIC TARGET; GLUTATHIONE-PEROXIDASE; 3; PHASE-II TRIAL; ANNEXIN A4; CISPLATIN RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; POOR-PROGNOSIS; PLATINUM RESISTANCE;

D O I：

10.1186/s12935-015-0267-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advances in surgical and medical treatments for ovarian cancer have improved prognoses. Platinum drugs in particular are pivotal for the medical treatment of ovarian cancer. However, previous studies have revealed that some histological subtypes, such as clear cell carcinoma, are resistant to medical treatment, including that with platinum drugs. Consequently, the clinical prognosis of advanced clear cell carcinoma is remarkably inferior, primarily because of its chemoresistant behavior. The prevalence of clear cell carcinoma is approximately 5 % in the West, but in Japan, its prevalence is particularly high, at approximately 25 %. Current medical treatments for advanced clear cell carcinoma are difficult to administer, and they have poor efficacy, warranting the development of novel target-based therapies. In this review, we describe medical treatments for clear cell carcinoma and discuss future prospects for therapy. In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1 beta, ZNF217. We also review targeted molecular therapeutics for epithelial ovarian cancer and discuss their role in clear cell carcinoma treatment. We review the drugs targeting angiogenesis (bevacizumab, sorafenib, and pazopanib), growth factors (gefitinib, erlotinib, lapatinib, trastuzumab, and AMG479), and signaling pathways (temsirolimus, dasatinib, and imatinib), and other drugs (oregovomab, volociximab, and iniparib). This current review summarizes and discusses the clinical significance of these factors in ovarian clear cell carcinoma as well as their potential mechanisms of action. It may provide new integrative understanding for future studies on their exact role in ovarian clear cell carcinoma.

引用

页数：13

共 100 条

[1] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[2] Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010 [J].

Anglesio, Michael S. ;

Carey, Mark S. ;

Koebel, Martin ;

MacKay, Helen ;

Huntsman, David G. .

GYNECOLOGIC ONCOLOGY, 2011, 121 (02) :407-415

[3]

[Anonymous], J CLIN ONCOL S

[4] Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada [J].

Aris, Aziz .

JOURNAL OF OVARIAN RESEARCH, 2010, 3

[5] A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer [J].

Bell-McGuinn, Katherine M. ;

Matthews, Carolyn M. ;

Ho, Steffan N. ;

Barve, Minal ;

Gilbert, Lucy ;

Penson, Richard T. ;

Lengyel, Ernst ;

Palaparthy, Rameshraja ;

Gilder, Kye ;

Vassos, Artemios ;

McAuliffe, William ;

Weymer, Sara ;

Barton, Jeremy ;

Schilder, Russell J. .

GYNECOLOGIC ONCOLOGY, 2011, 121 (02) :273-279

[6] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers [J].

Bitler, Benjamin G. ;

Aird, Katherine M. ;

Garipov, Azat ;

Li, Hua ;

Amatangelo, Michael ;

Kossenkov, Andrew V. ;

Schultz, David C. ;

Liu, Qin ;

Shih, Ie-Ming ;

Conejo-Garcia, Jose R. ;

Speicher, David W. ;

Zhang, Rugang .

NATURE MEDICINE, 2015, 21 (03) :231-+

[7] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].

Bookman, MA ;

Darcy, KM ;

Clarke-Pearson, D ;

Boothby, RA ;

Horowitz, IR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290

[8] Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance [J].

Bruhn, Oliver ;

Cascorbi, Ingolf .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (10) :1337-1354

[9] Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling [J].

Chandler, Ronald L. ;

Damrauer, Jeffrey S. ;

Raab, Jesse R. ;

Schisler, Jonathan C. ;

Wilkerson, Matthew D. ;

Didion, John P. ;

Starmer, Joshua ;

Serber, Daniel ;

Yee, Della ;

Xiong, Jessie ;

Darr, David B. ;

de Villena, Fernando Pardo-Manuel ;

Kim, William Y. ;

Magnuson, Terry .

NATURE COMMUNICATIONS, 2015, 6

[10] GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response [J].

Chen, Baishen ;

Rao, Xi ;

House, Michael G. ;

Nephew, Kenneth P. ;

Cullen, Kevin J. ;

Guo, Zhongmin .

CANCER LETTERS, 2011, 309 (01) :37-45

← 1 2 3 4 5 6 7 8 9 10 →